Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Syndax Revuforj Data at EHA 2026
Tech clinical trial data

Syndax Revuforj Data at EHA 2026

Analysis based on 7 articles · First reported May 12, 2026 · Last updated May 12, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive clinical data for Revumenib (revumenib) presented by Syndax Pharmaceuticals at EHA 2026 is expected to have a positive impact on Syndax Pharmaceuticals' stock price, as it reinforces the drug's potential to transform acute leukemia treatment. This could lead to increased investor confidence and potential future revenue growth for Syndax Pharmaceuticals.

Biotechnology Pharmaceuticals
Event Summary

Syndax Pharmaceuticals announced the release of 12 abstracts for its drug Revumenib (revumenib) that will be presented at the European Hematology Association (EHA) 2026 Congress. The abstracts highlight strong activity of Revumenib across various acute leukemia subtypes, including KMT2Ar, NPM1m, and NUP98r acute leukemias. New real-world data demonstrate compelling outcomes and favorable tolerability with Revumenib monotherapy and combination use. Encouraging results were also observed with Revumenib in the post-transplant setting, showing favorable outcomes compared to historical data and potentially reducing the risk of relapse after stem cell transplantation. Additionally, frontline and R/R combination data for Revumenib show high rates of MRD negativity, transplant, and favorable tolerability. These findings bolster Syndax Pharmaceuticals' scientific leadership in menin inhibition and its confidence in transforming the treatment paradigm for a significant portion of patients with AML.

Key Actions
100 Syndax Pharmaceuticals highlighted data release European Hematology Association
90 Revumenib showed strong activity
80 Revumenib showed compelling outcomes
Entities Involved
stock
Syndax Pharmaceuticals
Syndax Pharmaceuticals highlighted positive clinical data for its drug Revumenib (revumenib) at the European Hematology Association (EHA) 2026 Congress, reinforcing its leadership in menin inhibition and potentially transforming acute leukemia treatment.
Importance 100 Sentiment 70
oth
Revumenib
Revumenib (revumenib) is an FDA-approved menin inhibitor developed by Syndax Pharmaceuticals, with new clinical data highlighting its strong activity across various acute leukemia subtypes.
Importance 90 Sentiment 70
ngo
European Hematology Association
The European Hematology Association (EHA) is hosting its 2026 Congress where Syndax Pharmaceuticals is presenting 12 abstracts related to Revumenib (revumenib).
Importance 30 Sentiment 0
per
Nick Botwood
Nick Botwood, Head of Research & Development and Chief Medical Officer at Syndax Pharmaceuticals, provided commentary on the significance of the Revumenib data presented at EHA 2026.
Importance 20 Sentiment 0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration (FDA) previously granted Orphan Drug Designation, Fast Track designation, and Breakthrough Therapy Designation to Revumenib (revumenib).
Importance 10 Sentiment 0
govactor
International — European Commission
The International — European Commission previously granted Orphan Drug Designation to Revumenib (revumenib) for the treatment of AML.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.